China Psoriasis Market Discussed by GlobalData in In-Demand Report Now Available at

09 Aug 2013 • by Natalie Aster

LONDON – In China, the absence of long-term effective therapies for psoriasis is one the most burning issues in the medical field. Currently available biologics therapies are rather effective and safe, but they are not perfect enough given their suppressive effect on the immune system and general misunderstanding of their exact mechanism of action.

New pipeline products are not expected to be launched in China over the next 8-10 years due to the existing commitment to certain brands in the country. Remicade, Taclonex and Methotrexate Sodium are some of the brands available in the country.

In-demand research report “PharmaPoint: Psoriasis - China Drug Forecast and Market Analysis to 2022” prepared by GlobalData provides a comprehensive guide to the country market for psoriasis.

The report offers an insightful analysis of the Chinese psoriasis market and discloses essential data on the country’s industry performance. It presents general disease overview including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines. The research study contains a detailed competitive assessment, profiles major companies and reviews their product portfolios. The report outlines the key market opportunities and examines the country’s unmet needs, includes an in-depth psoriasis pipeline analysis and SWOT analysis, scrutinizes main factors driving and restraining the market. In addition, future outlook for the Chinese psoriasis market along with sales forecast for the top drugs in China up to 2022 is offered in the study.

Report Details:

PharmaPoint: Psoriasis - China Drug Forecast and Market Analysis to 2022
Published: May, 2013
Pages: 93
Price: US$ 4,995.00

More Psoriasis Country Market Research Studies by GlobalData Include:

More market research studies by the publisher can be found at GlobalData page.



The Market Publishers, Ltd.
Tanya Levdikova
Tel: +44 208 144 6009
Fax: +44 207 900 3970